Improving Obesity Care: A Practical Guide to Engaging and Treating Patients- Webcast

Begin

Learning Objectives:

• Incorporate key measures and updated algorithms for risk when assessing patients for obesity and its comorbidities
• Recognize obesity as a disease and understand associated barriers to initiating and maintaining care
• Evaluate and apply intensive lifestyle interventions that take effectiveness, access to support, and patient preference into consideration
• Apply evidence-based guidelines in the selection and use of pharmacotherapy to treat patients with obesity that takes risk factors into consideration
• Devise patient-centered strategies to overcome challenges in long-term weight loss maintenance

Credits:
2.50 ABIM MOC
2.50 AMA PRA Category 1 Credits™

The Future of Cholesterol Management: Application of PCSK9 Inhibitors in Practice 2018- Webcast

Begin

Learning Objectives:

• Discuss the biology and genetic underpinnings of dyslipidemia as it relates to PCSK9 and the LDL receptor
• Assess the value of newer therapies to treat patients with familial hypercholesterolemia and apply treatment
• Evaluate strategies to optimize commonly used lipid-lowering therapies in patients with familial hypercholesterolemia

Credits:
2.0 ABIM MOC
2.0 AMA PRA Category 1 Credits™

New and Emerging Options in Osteoporosis: Improving Strategies and Outcomes in Practice- Webcast

Begin

Learning Objectives:

• Describe existing clinical challenges in the diagnosis and management of osteoporosis and identify common barriers in management
• Apply current guidelines and state of care methods when assessing and treating patients at risk for low trauma fractures or living with osteoporosis
• Interpret the mechanism of action, benefits, and limitations of emerging osteoporosis therapies, and recognize the potential impact of current trials on practice

Credits:
2.50 ABIM MOC
2.50 AMA PRA Category 1 Credits™

Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer - Webcast

Begin

Learning Objectives:

• Personalize treatment selection for patients with RAI-refractory DTC based on available data and approved agents
• Implement strategies to mitigate toxicities associated with RAI-refractory DTC therapies
• Evaluate data from late-stage clinical trials of emerging therapies for RAI-refractory DTC

Credits:
1.0 AMA PRA Category 1 Credits™

Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline Educational Activity

Begin

Learning Objectives:

• Diagnose central precocious puberty in male childhood cancer survivors exposed to gonadotoxic therapy.
• Explain how GH deficiency and central precocious puberty may occur together, making it difficult to interpret linear growth data.
• Diagnose non–GH-related causes of growth failure such as spinal irradiation.
• Accurately interpret thyroid function tests in patients at risk for primary and central hypothyroidism.
• Explain the importance of the synergistic action of GH and sex hormones in the growing adolescent.
• Explain the risk for exacerbation of the symptoms of adrenal insufficiency in individuals on thyroid replacement and untreated central adrenal insufficiency.

Credits:
0.5 AMA PRA Category 1 Credits™

Endocrine Treatment of Gender-Dysphoric/ Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline Educational Activity

Begin

Learning Objectives:

• List significant changes in the evidence base for Gender Dysphoria /Gender Incongruence since publication of the previous ES guideline on this topic.
• Define significant changes in best practices that are being recommended in the 2017 Gender Dysphoria/Gender Incongruence guideline due to changes in science.
• Identify gaps in the existing evidence base for Gender Dysphoria /Gender Incongruence which contribute to controversy or disagreement among clinicians about standards for optimal patient care.

Credits:
1.0 ABIM MOC
1.0 ABP MOC
1.0 AMA PRA Category 1 Credits™